DMD and Duchenne muscular dystrophy: Monitoring biomarker candidates for DMD tend to have a longitudinal trajectory associated with patient age [1, 2, 6, 8] and it is assumed that these trajectories will change toward healthy trajectories upon increased partial dystrophin re-expression and reduced pathology.